<div class="headers"><div>Figure 1 Percentage of patients with CCV AEs according to presence or not of cardiovascular risk factors at baseline.IND Z indacaterol (150, 300 and 600 Z mg doses); FORM Z formoterol; SALM Z salmeterol; TIO Z tiotropium; PBO Z placebo; BMI Z body mass index (kg/m2); DM Z diabetes mellitus.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>11(K)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='text-align: left;'>1</td>
<td style='text-align: left;'>1</td>
<td style='text-align: left;'><p class="">Figure 1 Percentage of patients with CCV AEs according to presence or not of cardiovascular risk factors at baseline.</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>2</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>2</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">IND Z indacaterol (150, 300 and 600 Z mg doses); FORM Z formoterol; SALM Z salmeterol; TIO Z tiotropium; PBO Z placebo; BMI Z body mass index (kg/m2); DM Z diabetes mellitus.</p></td>
</tr>
</tbody>
</table>
